{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Approved","title":"Allergan: Botox, Rogue Scientists, and the Ultimate Beauty Franchise","html":"","width":"100%","height":180,"duration":12996,"description":"The wild story of how a Cold War bioweapon became Botox — and how Allergan turned a sleepy ophthalmology drug into an enduring aesthetic franchise.\nEvery part of this story looks nothing like your normal blockbuster drug. Botox started its development storyas a Cold War bioweapon so lethal the CIA was thinking of using it on Castro. Decades later, an eye surgeon in San Francisco mortgaged his house and managed to bootstrap his way to a BLA– no venture capital needed! After a contentious sale to a sleepy eye-drop company called Allergan, it turned Botox into one of the most durable, recurring-revenue franchises in the history of medicine. \nThat cash cow provoked all sorts of financial battles–  a hostile takeover attempt involving Bill Ackman, a tax-inversion scheme with Pfizer that united Bernie Sanders and Donald Trump in opposition, and a far-fetched plan to rent a Native American tribe's sovereign immunity to protect a different drug's patents.\n\nIn this episode, we trace Botox from a 19th-century German sausage poisoning, through a Cold War weapons lab, an eye surgeon's garage-scale manufacturing operation, and into Allergan's decades-long reign — covering the science of why the drug still has no biosimilar, the \"aesthetics stack\" that turned it into a subscription business for faces, and the corporate finance drama (Valeant, Actavis, Pfizer and AbbVie) that followed. Along the way: exclusive interviews with Allergan's 95-year-old founding CEO, the scientist who helped manufacture the original drug substance in an academic lab, and the dermatologist who tried to repurpose Botox to treat depression.\nIn this episode:\nHow a Clostridium botulinum strain donated for free by a Harvard professor became the physical basis of a multi-billion-dollar drug\nWhy the FDA's insistence on unique nonproprietary names (onabotulinumtoxinA vs. abobotulinumtoxinA) created an accidental, unbreakable competitive moat\nHow Allergan built the \"surround the ophthalmologist\" sales...","thumbnail_url":"https://img.transistorcdn.com/xbQufpFbhRau2U4ClIm4xzSaMv0jHm9xAp7Oakfo6XA/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8zMmM2/ZjdmYzNmMTM4ODMx/NjkxMDlmNGQ3ODY2/YjFjMy5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}